Analysis of the tumoricidal and anti-cachectic potential of curcumin

Anticancer Research

Volumn 34, Issue 9, 2014, Pages 4781-4788

  Oelkrug, Christopher ^a   Marie Lange, Christina ^a   Wenzel, Elisabeth ^a   Fricke, Stephan ^a,b   Hartke, Martin ^a   Simasi, Jacinta ^a   Schubert, Andreas ^a  

^a FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

B16; C2C12.; Cachexia; Curcumin; Cytotoxicity

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; CASPASE 3; CASPASE 7; CURCUMIN; MELANIN; CASPASE; GLYCOPROTEIN; MALANIN; TOXIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SOLUTION; DRUG STABILITY; EC50; ENZYME ACTIVITY; IMPEDANCE; IN VITRO STUDY; INCUBATION TIME; MELANOMA B16; MONOLAYER CULTURE; MOUSE; MUSCLE ATROPHY; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ATROPHY; B16; C2C12; CACHEXIA; CELL DEATH; CELL SURVIVAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENZYME ACTIVATION; EXPERIMENTAL MELANOMA; HYPERTROPHY; IC 50; METABOLISM;

B16; C2C12; CACHEXIA; CURCUMIN; CYTOTOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; ATROPHY; CACHEXIA; CASPASES; CELL DEATH; CELL SURVIVAL; CURCUMIN; ENZYME ACTIVATION; GLYCOPROTEINS; HYPERTROPHY; INHIBITORY CONCENTRATION 50; MELANOMA, EXPERIMENTAL; MICE; TOXINS, BIOLOGICAL;

EID: 84908668369     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Ammon HPT and Wahl M: Pharmacology of Curcuma longa. Planta Medica 57: 1-7, 1991.
2. Kuttan R, Bhanumathy P, Nirmala K and George MC: Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett 29: 197-202, 1985.
3. Santel T, Pflug G, Hemdan NY, Schäfer A, Hollenbach M, Buchold M, Hintersdorf A, Lindner I, Otto A, Bigl M, Oerlecke I, Hutschenreuther A, Sack U, Huse K, Groth M, Birkemeyer C, Schellenberger W, Gebhardt R, Platzer M, Weiss T, Vijayalakshmi MA, Krüger M and Birkenmeier G: Curcumin inhibits glyoxalase 1: a possible link to its anti-inflammatory and antitumor activity. PLoS One 3(10): e3508, 2008.
4. Odot J, Albert P, Carlier A, Tarpin M, Devy J and Madoulet Cl: In vitro and In vitro anti-tumoral effect of curcumin against melanoma cells. Int J Cancer 111: 381-387, 2004.
5. Srivastava KC, Bordia A, and Verma SK: Curcumin, a major component of food spice turmeric (Curcuma longa ) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins, Leukotrienes and Essential Fatty Acids 52: 223-227, 1995.
6. Varalakshmi C, Ali AM, Pardhasaradhi BV, Srivastava RM, Singh S and Khar A: Immunomodulatory effects of curcumin: in-vivo. International Immunopharmacology 8: 688-700, 2008.
7. Lin CM, Lee JF, Chiang LL, Chen CF, Wang D and Su CL: The protective effect of curcumin on ischemia-reperfusion-induced liver injury. Transplantation Proceedings 44: 974-977, 2012.
8. Lin MS, Hung KS, Chiu WT, Sun YY, Tsai SH, Lin JW and Lee YH: Curcumin enhances neuronal survival in N-methyl-d-aspartic acid toxicity by inducing RANTES expression in astrocytes via PI-3K and MAPK signaling pathways. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35(4): 931-938, 2011.
9. Hartojo W, Silvers AL, Thomas DG, Seder CW, Lin L, Rao H, Wang Z, Greenson JK, Giordano TJ, Orringer MB, Rehemtulla A, Bhojani MS, Beer DG and Chang AC: Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor κB in esophageal adenocarcinoma. Translational oncology 3(2): 99, 2010.
10. Karunagaran D, Rashmi R and Kumar TR: Induction of apoptosis by curcumin and its implications for cancer therapy. Current Cancer Drug Targe 5: 117-129, 2005.
11. Tan TW, Tsai HR, Lu HF, Lin HL, Tsou MF, Lin YT, Tsai HY, Chen YF and Chung JG: Curcumin-induced cell cycle arrest and apoptosis in human acute promyelocytic leukemia HL-60 cells via MMP changes and caspase-3 activation. Anticancer Res 26: 4361-4372, 2006.
12. Woo JH, Kim YH, Choi YJ, Kim DG, Lee KS, Bae JH, Min DS, Chang JS, Jeong YJ, Lee YH, Park JW and Kwon TK: Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of BCL-XL and IAP, the release of cytochrome c and inhibition of AKT. Carcinogenesis 24: 1199-1208, 2003.
13. Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY and Lin JK: Stability of curcumin in buffer solutions and characterization of its degradation products. Journal of Pharmaceutical and Biomedical Analysis 15: 1867-1876, 1997.
14. Huang MT, Smart RC, Wong CQ and Conney AH: Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Research 48: 5941-5946, 1988.
15. Kanskia J, Aksenovaa M, Stoyanovaa A and Butterfield DA: Ferulic acid antioxidant protection against hydroxyl and peroxyl radical oxidation in synaptosomal and neuronal cell culture systems in vitro: structure-activity studies. The Journal of Nutritional Biochemistry 13: 273-281, 2002.
16. Srinivasan M, Sudheer AR and Menon VP: Ferulic Acid: Therapeutic potential through its antioxidant property. J Clin Biochem Nutr 40: 92-100, 2007.
17. Sultana R, Ravagna A, Mohmmad-Abdul H, Calabrese V, Butterfield D: Ferulic acid ethyl ester protects neurons against amyloid beta-peptide(1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J Neurochem 92: 749-758, 2005.
18. Yan JJ, Cho JY, Kim HS, Kim KL, Jung JS, Huh SO, Suh HW, Kim YH and Song DK: Protection against beta-amyloid peptide toxicity In vitro with long-term administration of ferulic acid. Br J Pharmacol 133: 89-96, 2001.
19. Makni M, Chtourou Y, Barkallah M and Fetoui H: Protective effect of vanillin against carbon tetrachloride (CCl4)-induced oxidative brain injury in rats. Toxicology and industrial health 28(7): 655-662, 2012.
20. Maknia M, Chtouroua Y, Fetouia H, Garouia EM, Boudawara T and Zeghal N: Evaluation of the antioxidant, anti-inflammatory and hepatoprotective properties of vanillin in carbon tetrachloride-treated rats. European J Pharmacol 668: 133-139, 2011.
21. Kampa M, Alexaki VI, Notas G, Nifli AP, Nistikaki A, Hatzoglou A, Bakogeorgou E, Kouimtzoglou E, Blekas G, Boskou D, Gravanis A and Castanas E: Antiproliferative and apoptotic effects of selective phenolic acids on T47D human breast cancer cells: potential mechanisms of action. Breast Cancer Res 6: R63-R74, 2004.
22. Shobal G, Joy D, Joseph T, Majeed M, Rajendran R and Srinivas PS: Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica 64: 353-356, 1998.
23. Theologides A: Cancer cachexia. Cancer 43: 2004-2012, 1979.
24. Busquets S, Almendro V, Barreiro E, Figueras M, Argilés JM and López-Soriano FJ: Activation of UCP gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. Involvement of ROS in a model of mouse cancer cachexia. FEBS Letters 3: 717-722, 2005.
25. Bosaeus I, Daneryd P and Lundholm K: Dietary intake, resting energy expenditure, weight loss and survival in cancer patients. J Nutr 132: 3465S-3466S, 2002.
26. Dhanapal R, Saraswathi T and Govind RN: Cancer cachexia. J Oral Maxillofac Pathol 15: 257-260, 2011.
27. Fearon KC, Voss AC and Hustead DS: Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83: 1345-1350, 2006.
28. Eley HL and Tisdale MJ: Skeletal muscle atrophy: a link between depression of protein synthesis and increase in degradation. J Biol Chem 282: 7087-7097, 2007.
29. Smith HJ, Mukerji P and Tisdale MJ: Attenuation of proteasome-induced proteolysis in skeletal muscle by β-hydroxy-β-methylbutyrate in cancer-induced muscle loss. Cancer Res 65: 277-283, 2005.
30. Strassmann G, Fong M, Kenney JS and Jacob CO: Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89: 1681-1684, 1992.
31. Springer J, Tschirner A, Hartman K, Palus S, Wirth EK, Ruis SB, Möller N, von Haehling S, Argiles JM, Köhrle J, Adams V, Anker SD and Doehner W: Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. Int J Cancer 131: 2187-2196, 2012.
32. Acharyya S and Guttridge DC: Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin Cancer Res 13: 1356-1361, 2007.
33. Rakhilin S, Turner G, Katz M, Warden R, Irelan J, Abassi YA and Glass DJ: Electrical impedance as a novel biomarker of myotube atrophy and hypertrophy. J Biomol Screen 16: 565-574, 2011.
34. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB and Aggarwal BB: Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 267(1): 133-164, 2008.
35. Jackson IJ, Chambers DM, Tsukamoto K, Copeland NG, Gilbert DJ, Jenkins NA and Hearing V: A second tyrosinase-related protein, TRP-2, maps to and is mutated at the mouse slaty locus. The EMBO Journal 11: 527-535, 1992.
36. Nishioka E, Funasaka Y, Kondoh H, Chakraborty AK, Mishima Y and Ichihashi M: Expression of tyrosinase, TRP-1 and TRP-2 in ultraviolet-irridiated human melanomas and melanocytes: TRP-2 protects melanoma cells from ultraviolet B-induced apoptosis. Melanoma Research 9: 433-443, 1999.
37. Anuchapreeda S, Fukumori Y, Okonogi S and Ichikawa H: Preparation of Lipid Nanoemulsions Incorporating Curcumin for Cancer Therapy. Journal of Nanotechnology 2012 (2012): 11 pages, 2012.
38. Busquets S, Carbó N, Almendro V, Quiles M T, López-Soriano F J and Argilés JM: Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. Cancer Letters 167(1): 33-88, 2001.
39. Aggarwal BB, Kumar A and Bharti AC: Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23(1A): 363-398, 2003.
40. Pfeiffer E, Höhle S, Solyom AM and Metzler M: Studies on the stability of turmeric constituents. Journal of Food Engineering 56: 257-259, 2003.